<DOC>
	<DOCNO>NCT02447601</DOCNO>
	<brief_summary>To assess effect PEX168 dose pharmacokinetics simvastatin ( determined simvastation acid ) healthy subject . To assess safety single dose simvastation administer without PEX168</brief_summary>
	<brief_title>Evaluate Pharmacokinetics Simvastatin When Coadministered With PEX168 Healthy Adult Subjects</brief_title>
	<detailed_description>This open-label , sequential , single-center study evaluate pharmacokinetics simvastatin coadministered PEX168 healthy adult subject . The total duration subject 's participation study approximately 10 week , include 14-day Screening Period , 34-day Treatment Period , approximately 4-week Follow-up Period . Center : This study conduct single site Shanghai Mental Health Center ( SMHC ) China Treatment.All subject receive single 40-mg oral dose simvastatin Day 1 follow 5 weekly 200μg dos PEX168 inject subcutaneously begin Day 3 second single 40-mg oral dose simvastatin Day 33 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>An individual met follow criterion eligible study . 1 . Healthy male age 18 45 year ( include end ) time sign informed consent . 2 . Weighing less 50kg，Body Mass Index ( BMI ) 18 25kg/m2 . 3 . No history cardiovascular , liver , kidney , gastrointestinal , neuropsychiatric disease , history drug allergy . 4 . Capable give write informed consent , include compliance requirement restriction list consent form . 1 . Known study drug allergy ( PEX168 , simvastatin ) similar drug allergy ( GLP1 receptor agonist , GLP1 analogue , statin ) allergic constitution ; 2 . Having Alcohol drug abuse within first 6 month screen ; 3 . Smoked within 3 month screen ; 4 . Received GLP1 receptor agonist , GLP1 analog , DPPIV inhibitor , similar structure drug treatment screening ; 5 . Following thorough medical examination , clinically significant abnormality find ; 6 . In screen period , blood pressure great 140 / 90mmHg , retest diagnosis pulse rate high 100bpm person ; 7 . In screen period , ECG QTc &gt; 450ms , diagnose retest ; 8 . In screen period , serum creatinine urine protein abnormal , determine clinically significant investigator ; 9 . In screen period , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) , γ glutamate GGT ( γGT ) , total bilirubin ( Tbil ) great normal range limit , investigator determines clinical significance ; 10 . In screen period , creatine kinase ( CK ) exceed upper limit normal range , judge investigator clinical significant ; 11 . In screen period , thyroid dysfunction ; 12 . Before screen history medullary thyroid cancer ; 13 . Having surgery ( include impact gastric empty gastrointestinal surgery ) within 6 month screen ; 14 . Participate blood donation donation amount ≥400ml within three month screen , participate blood donation blood transfusion within month ; 15 . Using tested drug may affect prescription drug , nonprescription drug , herb , food ( grapefruit juice ) food supplement person 2 week screen ; 16 . Drinking medication caffeinecontaining xanthine food beverage ( list annex 3 ) , strenuous exercise , effect drug absorption , distribution , metabolism , excretion factor 2 day screen . 17 . Any clinically significant investigator determine acute disease Screening occur within month ; 18 . There history pancreatitis acute pancreatitis screening ; 19 . Having dyslipidemia , coronary heart disease , history high cholesterol screen . 20 . There lung disease history , history chronic liver gallbladder disease , cholecystitis history , history bladder disease , history colon inflammation screen . 21 . Within three month screen participated drug medical device clinical trial ( include placebo ) ; 22 . Hepatitis B surface antigen , hepatitis C antibody , HIV antibody , syphilis antibody test positive ; 23 . Reluctant take effective contraceptive method contraception . During trial , family planning within six month spouses trial last dose ( first 33 day ) ; 24 . The investigator believe situation might lead subject complete subject study bring significant risk .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>